Breaking News

JSR Life Sciences’ Amsphere A3 Leveraged in FDA-Approved Antibody Therapy

Launch marks product’s first use in a commercial therapeutic.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

JSR Life Sciences, LLC’s lead product, Amsphere A3 has been incorporated for the first time into the commercial manufacturing of an FDA-approved treatment.     Amsphere A3 is a next-gen Protein-A chromatography resin that enables advanced protein separation in downstream processing of therapeutic antibodies. Since its launch in January 2016, the product has seen rapid adoption as an alternative option for downstream purification in biologics processing.   “The support provided by our global ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters